Edison Issues Outlook on Oryzon Genomics (ORY)

     (Logo: http://photos.prnewswire.com/prnh/20130417/608168 )

We have increased our valuation of Oryzon from €266m to €308m or €9.0/share (from €9.3/share) on the back of the recent financing round and higher success probability for AD. The main potential catalysts over the next 12-24 months are progress in the SCLC trial run by Roche, initiation of Phase II trials in neurodegenerative disorders with ORY-2001, new preclinical candidates entering the clinic and delivering first human data.  

Click here to view the full report.

All reports published by Edison are available to download free of charge from its website

http://www.edisoninvestmentresearch.com

About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

Contact details: Learn more at http://www.edisongroup.com and connect with Edison on:  
    
    LinkedIn http://www.linkedin.com/company/edison-investment-research
    Twitter  http://www.twitter.com/Edison_Inv_Res
    YouTube  http://www.youtube.com/edisonitv
    Google+  https://plus.google.com/105425025202328783163/posts

For more information please contact:
Jonas Peciulis
Edison Investment Research
+44(0)20-3077-5728

Juan Pedro Serrate
Edison Investment Research
+44(0)20-3681-2534
[email protected]

SOURCE Edison Investment Research